Myqorzo improves symptoms in Phase 3 genetic heart disease trial
Updated
Updated · STAT · May 5
Myqorzo improves symptoms in Phase 3 genetic heart disease trial
9 articles · Updated · STAT · May 5
Cytokinetics said the ACACIA study met dual efficacy goals with statistical significance in patients with non-obstructive hypertrophic cardiomyopathy.
The drug improved heart failure symptoms and cardiovascular fitness, potentially extending treatment beyond the more severe obstructive form of hypertrophic cardiomyopathy.
If regulators clear the expanded use, analyst forecasts suggest Myqorzo's peak annual sales could reach $5 billion.
How did Cytokinetics' drug succeed where its main rival, Camzyos, failed in treating this common heart condition?
Myqorzo improves symptoms but carries a heart failure risk. What is the real-world safety balance for patients?